ErinALarkinsMD

Oncology • Bethesda, MD

Assistant Professor, Medicine, Uniformed Services Hebert SOM

Join to view full profile

Are you Dr. Larkins?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 35 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
8901 Wisconsin Ave
Wrnmmc, Dept Of Hem-Onc, America Bldg, 3rd Floor
Bethesda, MD 20889
Phone+1 301-319-2131
Is this information wrong?

Summary

Dr. Erin Larkins, MD is an oncologist in Bethesda, Maryland. She is currently licensed to practice medicine in Virginia. She is an Assistant Professor at Uniformed Services Hebert SOM.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 2000

Certifications & Licensure

VA State Medical License 2001 - 2026
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled anal...
Bernardo Haddock Lobo Goulart, Sirisha L Mushti, Somak Chatterjee, Erin Larkins, Pallavi S Mishra-Kalyani, Richard Pazdur, Paul G Kluetz, Harpreet Singh> ;The Lancet. Oncology. 2024 Apr 1
1 citations
Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.
Bernardo H L Goulart, Erin Larkins, Julia A Beaver, Harpreet Singh> ;Journal of Clinical Oncology. 2023 Aug 10
1 citations
Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data.
Qi Liu, Chenan Zhang, Yue Huang, Ruihao Huang, Shiew-Mei Huang, Erin Larkins, Liza Stapleford, Donna R Rivera, Paul G Kluetz, Shenggang Wang, Hao Zhu, James Weese, Eli...> ;Cancer Research Communications. 2023 Feb 1
5 citations
A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.
David E Gerber, Harpreet Singh, Erin Larkins, Andrea Ferris, Patrick M Forde, Wendy Selig, Upal Basu Roy> ;JAMA Oncology. 2022 Sep 1
31 citations
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, Luckson N Mathieu, Yi Ren, Joyce Cheng, Mallorie H Fiero, Wentao Fu, Youwei Bi, Shyam Kalavar, Samina Jafri, Pallav...> ;Clinical Cancer Research. 2022 Jun 1
Blurring the Lines of Design: Prospective Observational Cohorts and Pragmatic Clinical Trials Characterizing Treatment Effects in Routine Cancer Care.
Donna R Rivera, Erin Larkins, Paul G Kluetz> ;The Oncologist. 2022 Mar 4
37 citations
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers WithGene Mutations or Fusions.
Kim, J., Bradford, D., Larkins, E., Pai-Scherf, L., Chatterjee, S., Mishra-Kalyani, P., Wearne, E., Helms, W., Ayyoub, A., Bi, Y., Sun, J., Charlab, R., Liu, J., Zhao,...> ;Clinical Cancer Research. 2021 Oct 15
23 citations
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Erica C Nakajima, Paz J. Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Youwei Bi, Hisham Qosa, Jiang Liu, Hong Zhao, Missiratch Biable, Lauren T...> ;Clinical Cancer Research. 2021 Aug 30
43 citations
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
, , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2021 Aug 3
5 citations
US Food and Drug Administration regulatory updates in neuro-oncology.
Gautam U Mehta, Amy Barone, Diana Bradford, Erin Larkins, Janice Kim, Lee Pai-Scherf, Adnan A. Jaigirdar, Mirat Shah, Suparna Wedam, Laleh Amiri-Kordestani, Marc R. Th...> ;Journal of Neuro-Oncology. 2021 Jun 22
62 citations
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
Luckson Mathieu, Sujay Shah, Lee Pai-Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodriguez, Pallavi S. Mishra-Kalyani, Kirsten B. Goldberg, Paul G. Kluetz...> ;The Oncologist. 2021 May 1
54 citations
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers withGene Mutations or Fusions.
Bradford, D., Larkins, E., Mushti, S., Rodriguez, L., Skinner, A., Helms, W., Price, L., Zirkelbach, J., Li, Y., Liu, J., Charlab, R., Turcu, F., Liang, D., Ghosh, S.,...> ;Clinical Cancer Research. 2021 Apr 15
132 citations
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal, Erin Larkins, Kirsten B. Goldberg, Norma Griffin, Karen Bijwaard, Eunice Y. Lee, Reena Philip, Xiaoping Jiang, ...> ;The Oncologist. 2018 Jun 1
45 citations
FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
Lauretta Odogwu, Luckson Mathieu, Kirsten B. Goldberg, Gideon M. Blumenthal, Erin Larkins, Mallorie H. Fiero, Lisa Rodriguez, Karen Bijwaard, Eunice Y. Lee, Reena Phil...> ;The Oncologist. 2018 Mar 1
145 citations
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Co...
Erin Larkins, Gideon M. Blumenthal, Weishi Yuan, Kun He, Rajeshwari Sridhara, Sriram Subramaniam, Hong Zhao, Chao Liu, Jingyu Yu, Kirsten B. Goldberg, Amy E. McKee, Pa...> ;The Oncologist. 2017 Jul 1
76 citations
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib
Erin Larkins, Gideon M. Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney Helms, Stacy Shifflett S...> ;Clinical Cancer Research. 2016 Nov 1
25 citations
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Pl...
Erin Larkins, Barbara Scepura, Gideon M. Blumenthal, Erik Bloomquist, Shenghui Tang, Missiratch Biable, Paul G. Kluetz, Patricia Keegan, Richard Pazdur> ;The Oncologist. 2015 Nov 1
21 citations
A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.
Khanh T. Do, Liang Cao, Zhigang Kang, Baris Turkbey, Maria Liza Lindenberg, Erin Larkins, Beata Holkova, Seth M. Steinberg, Mark Raffeld, Cody J. Peer, William D. Figg...> ;Clinical Colorectal Cancer. 2015 Sep 1
Losing ground: NIH funding to New York State researchers.
Sturman, L. S., Sorin, M. D., Larkins, E., Cavanagh, K. A., DeBuono, B. A.> ;Bull N Y Acad Med. 1997
Join now to see all

Press Mentions

Dr. David Gerber, University of Texas Southwestern, and LUNGevity Foundation Publish Recommendations to Simplify and Harmonize Lung Cancer Clinical TrialsAugust 30th, 2022